The objective of the ONTARGET study was to determine if:

(a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of CV death, MI, stroke or hospitalization for CHF compared with ramipril 10mg alone; and;

(b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.

Primary endpoints:

  • Cardiovascular death
  • Non-fatal myocardial infarction
  • Non-fatal stroke
  • Hospitalization for congestive heart failure.

Secondary endpoints:

  • Newly diagnosed CHF
  • CV revascularization procedures
  • Newly diagnosed diabetes
  • Cognitive decline (adjudication done by a special committee)
  • New onset of atrial fibrillation
  • Nephropathy

All primary and secondary endpoints were adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized, double-blind, parallel group

NO. of Countries


NO. of Sites


NO. of Participants


Study Period



Boehringer Ingelheim

Boehringer Ingelheim

Back To Top